|
1
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2012. CA Cancer J Clin. 62:10–29. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Forner A, Llovet JM and Bruix J:
Hepatocellular carcinoma. Lancet. 379:1245–1255. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Aravalli RN, Steer CJ and Cressman EN:
Molecular mechanisms of hepatocellular carcinoma. Hepatology.
48:2047–2063. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Warburg O: On the origin of cancer cells.
Science. 123:309–314. 1956. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Mathupala SP, Ko YH and Pedersen PL:
Hexokinase-2 bound to mitochondria: Cancer's stygian link to the
‘Warburg Effect’ and a pivotal target for effective therapy. Semin
Cancer Biol. 19:17–24. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Singh PK, Mehla K, Hollingsworth MA and
Johnson KR: Regulation of aerobic glycolysis by microRNAs in
cancer. Mol Cell Pharmacol. 3:125–134. 2011.PubMed/NCBI
|
|
7
|
Nie H, Li J, Yang XM, Cao QZ, Feng MX, Xue
F, Wei L, Qin W, Gu J, Xia Q and Zhang ZG: Mineralocorticoid
receptor suppresses cancer progression and the Warburg effect by
modulating the miR-338-3p-PKLR axis in hepatocellular carcinoma.
Hepatology. 62:1145–1159. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Zhang LF, Lou JT, Lu MH, Gao C, Zhao S, Li
B, Liang S, Li Y, Li D and Liu MF: Suppression of miR-199a
maturation by HuR is crucial for hypoxia-induced glycolytic switch
in hepatocellular carcinoma. EMBO J. 34:2671–2685. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Wang B, Hsu SH, Frankel W, Ghoshal K and
Jacob ST: Stat3-mediated activation of microRNA-23a suppresses
gluconeogenesis in hepatocellular carcinoma by down-regulating
glucose-6-phosphatase and peroxisome proliferator-activated
receptor gamma, coactivator 1 alpha. Hepatology. 56:186–197. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)). Method. 25:402–408. 2001. View Article : Google Scholar
|
|
11
|
Zhong JH, Xiang BD, Gong WF, Ke Y, Mo QG,
Ma L, Liu X and Li LQ: Comparison of long-term survival of patients
with BCLC stage B hepatocellular carcinoma after liver resection or
transarterial chemoembolization. PLoS One. 8:e681932013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Meng X, Chen X, Lu P, Ma W, Yue D, Song L
and Fan Q: MicroRNA-202 inhibits tumor progression by targeting
LAMA1 in esophageal squamous cell carcinoma. Biochem Biophys Res
Commun. 473:821–827. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Yi Y, Li H, Lv Q, Wu K and Zhang W, Zhang
J, Zhu D, Liu Q and Zhang W: miR-202 inhibits the progression of
human cervical cancer through inhibition of cyclin D1. Oncotarget.
7:72067–72075. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zhao Z, Lv B, Zhang L, Zhao N and Lv Y:
miR-202 functions as a tumor suppressor in non-small cell lung
cancer by targeting STAT3. Mol Med Rep. 16:2281–2289. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Yang J, Fan B, Zhao Y and Fang J:
MicroRNA-202 inhibits cell proliferation, migration and invasion of
glioma by directly targeting metadherin. Oncol Rep. 38:1670–1678.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zhang Y, Zheng D, Xiong Y, Xue C, Chen G,
Yan B and Ye Q: miR-202 suppresses cell proliferation in human
hepatocellular carcinoma by downregulating LRP6
post-transcriptionally. FEBS Lett. 588:1913–1920. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Li M, Jin R, Wang W, Zhang T, Sang J, Li
N, Han Q, Zhao W, Li C and Liu Z: STAT3 regulates glycolysis via
targeting hexokinase 2 in hepatocellular carcinoma cells.
Oncotarget. 8:24777–24784. 2017.PubMed/NCBI
|
|
18
|
Sun X and Zhang L: MicroRNA-143 suppresses
oral squamous cell carcinoma cell growth, invasion and glucose
metabolism through targeting hexokinase 2. Biosci Rep. 37(pii):
BSR201604042017. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Wang Y, Yun Y, Wu B, Wen L, Wen M, Yang H,
Zhao L, Liu W, Huang S, Wen N and Li Y: FOXM1 promotes
reprogramming of glucose metabolism in epithelial ovarian cancer
cells via activation of GLUT1 and HK2 transcription. Oncotarget.
7:47985–47997. 2016.PubMed/NCBI
|
|
20
|
Jin F, Wang Y, Zhu Y, Li S, Liu Y, Chen C,
Wang X, Zen K and Li L: The miR-125a/HK2 axis regulates cancer cell
energy metabolism reprogramming in hepatocellular carcinoma. Sci
Rep. 7:30892017. View Article : Google Scholar : PubMed/NCBI
|
